Geneva v. Marsam
Geneva filed a countersuit against its joint venture partner following the break-down of settlement negotiations, alleging that generics injectables maker Marsam has contacted "existing Geneva/Marsam customers and request[ed] to sell products under the Marsam label during the period that the partners were attempting to resolve matters in dispute" ("The Pink Sheet" Aug. 31, In Brief). In a July 22 lawsuit, Marsam charged that Geneva has "engaged in a secret course of self-dealing at Marsam's expense" ("The Pink Sheet" July 27, T&G 1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth